These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21919608)

  • 21. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule.
    Jang SH; Wientjes MG; Au JL
    J Pharmacol Exp Ther; 2001 Mar; 296(3):1035-42. PubMed ID: 11181938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy.
    Parhi P; Mohanty C; Sahoo SK
    Drug Discov Today; 2012 Sep; 17(17-18):1044-52. PubMed ID: 22652342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic profiles of doxorubicin in combination with taxanes.
    Holmes FA; Rowinsky EK
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):8-14. PubMed ID: 11552225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
    Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
    Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues.
    Kim M; Gillies RJ; Rejniak KA
    Front Oncol; 2013 Nov; 3():278. PubMed ID: 24303366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Side-on binding of p-sulphonatocalix[4]arene to the dinuclear platinum complex trans-[{PtCl(NH3)2}2mu-dpzm]2+ and its implications for anticancer drug delivery.
    Wheate NJ; Abbott GM; Tate RJ; Clements CJ; Edrada-Ebel R; Johnston BF
    J Inorg Biochem; 2009 Mar; 103(3):448-54. PubMed ID: 19171382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functionalized carbon nanotubes for anticancer drug delivery.
    Lay CL; Liu J; Liu Y
    Expert Rev Med Devices; 2011 Sep; 8(5):561-6. PubMed ID: 22026621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mathematical modeling of vesicle drug delivery systems 2: targeted vesicle interactions with cells, tumors, and the body.
    Ying CT; Wang J; Lamm RJ; Kamei DT
    J Lab Autom; 2013 Feb; 18(1):46-62. PubMed ID: 22989771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mathematical modeling of polymer erosion: consequences for drug delivery.
    Sackett CK; Narasimhan B
    Int J Pharm; 2011 Oct; 418(1):104-14. PubMed ID: 21130849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
    Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
    Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mathematical modeling of drug dissolution.
    Siepmann J; Siepmann F
    Int J Pharm; 2013 Aug; 453(1):12-24. PubMed ID: 23618956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys.
    Xu L; Zuch CL; Lin YS; Modi NB; Lum BL
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):607-14. PubMed ID: 17549476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles.
    Gautier J; Allard-Vannier E; Munnier E; Soucé M; Chourpa I
    J Control Release; 2013 Jul; 169(1-2):48-61. PubMed ID: 23567046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug.
    Ahmed F; Pakunlu RI; Brannan A; Bates F; Minko T; Discher DE
    J Control Release; 2006 Nov; 116(2):150-8. PubMed ID: 16942814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance.
    Levasseur LM; Slocum HK; Rustum YM; Greco WR
    Cancer Res; 1998 Dec; 58(24):5749-61. PubMed ID: 9865733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
    Greish K
    Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
    Mita AC; Olszanski AJ; Walovitch RC; Perez RP; MacKay K; Tuck DP; Simmons C; Hammond S; Mita MM; Beeram M; Stone AJ; Rowinsky EK; Lewis LD
    Clin Cancer Res; 2007 Jun; 13(11):3293-301. PubMed ID: 17545535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.